The University of Texas at San Antonio is an emerging Tier One research institution with nearly 29,000 students.
Principal Investigator(s)
Cardona, Astrid
Funded by
Natl Inst of Health
In the diabetic retina disruption of fractalkine (FKN) signaling induces fibrin(ogen) deposition. increased production of IL-1??? by microglia. vascular and neuronal damage.But. how FKN and its receptor. CX3CR1. regulate microglia activation and retinal pathology is unknown.In humans. two single nucleotide polymorphisms in the CX3CR1 locus (hCX3CR1-I249/M280) that show defective binding to FKN. play a key role in inflammation during diabetes.Induction of diabetes in a mouse model expressing the human CX3CR1-I249/M280 revealed accelerated neuronal loss in the retina.
The University of Texas at San Antonio is an emerging Tier One research institution with nearly 29,000 students.
Principal Investigator(s)
Golob, Edward
Alaeddini, Adel
Funded by
Southwest Res Inst
Lung cancer is the leading cause of cancer death in the United States. with approximately 135.000 Americans dying of the disease each year. A 2017 report by the City of San Antonio Metropolitan Health District identified cancer as the 2 cause of death amongst Bexar County residents and predicted that by 2020 it would become the leading cause of death [1]. To mitigate its impact. the United State Preventative Task Force recommends annual radiologic screening with computed tomography (CT) in at risk individuals [2]. During this screening process.
The University of Texas at San Antonio is an emerging Tier One research institution with nearly 29,000 students.
Principal Investigator(s)
Han, Hai-Chao
Funded by
UTSA VPR Office
This project will develop a method to obtain the fine structure of trabeculae carneae in human heart and establish a computation human heart model with these fine structure details. it will be a powerful tool to develop a trabecular cutting technique to treat patients with heart failure with preserved ejection fraction.
The University of Texas at San Antonio is an emerging Tier One research institution with nearly 29,000 students.
Principal Investigator(s)
McHardy, Stanton
Funded by
Univ of TX MD Anderson Cancer Ctr 506
The Center for Innovative Drug Discovery (CIDD) will provide Dr. Kunal Rai at the University of Texas MD Anderson Cancer Center with the custom synthesis of PROTACs and CIDD-0150877 analogs to support their research on YAP1 degraders. The CIDD will provide the compound design on new analogs to prepare. along with the detailed experimental conditions and analytical data associated with the established synthesis routes. The CIDD will design specific analogs based on the testing results and provide full medicinal chemistry support to optimize compounds. YAP1 potency. selectivity.
